All In Biotech

Drug Trial Radar · NCT05537038

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

A Phase Ia, Randomized, Placebo-controlled, Double-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in IGRA-negative, BCG naïve Subjects

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Apr 18, 2023

Primary completion

Jun 6, 2025

Study completion Dec 8, 2025

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Sep 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized, placebo-controlled, double-blind, safety and dose-finding Phase Ia trial will evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule.

Conditions

  • Tuberculosis

Interventions

  • BNT164a1Biological

    Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

  • BNT164b1Biological

    Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of solicited local reactions (pain, erythema/redness, induration/swelling) at the injection site up to 7 days after each doseTime frame: Up to 7 days after each dose
  2. Frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue, muscle pain and joint pain, chills, and fever) up to 7 days after each doseTime frame: Up to 7 days after each dose
  3. Proportion of participants with at least one adverse event (AE) occurring from each dose to 28 days after each doseTime frame: From Day 1 until Day 197
  4. Proportion of participants with at least one AE occurring from Dose 1 to 28 days post-Dose 3Time frame: From Day 1 until Day 197
  5. Proportion of participants with at least one serious adverse event (SAE) or medically attended adverse event (MAAE) occurring from Dose 1 up to 168 days post-Dose 3Time frame: From Day 1 until Day 337
  6. Number of AEs from Dose 1 to 28 days post-Dose 3Time frame: From Day 1 until Day 197

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • emovis GmbH

    Berlin, Germany

  • CRS Clinical Research Services Berlin GmbH

    Berlin, Germany

  • CRS Clinical Research Services Mannheim GmbH

    Mannheim, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.